Sign inJoin waitlistJoin the waitlist

Mark Pomerantz

Clinical Director, Lank Center for Genitourinary Oncology · Mass General Brigham

Credentials: · · ·

History

Lank Center for Genitourinary Oncology · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2004–2007
Internal Medicine
Brigham and Women's Hospital
2001–2004
Stanford University School of Medicine
1997–2001
Yale University
1993–1997

Research

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
Nature Genetics · 2009 · First of 26 authors · 551 citations
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Nature Genetics · 2015 · First of 18 authors · 386 citations
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC
Proceedings of the National Academy of Sciences of the United States of America · 2010 · 305 citations

Matthew Freedman
68 papers
PK
Philip Kantoff
42 papers
Toni Choueiri
26 papers
CS
Christopher Sweeney
19 papers
Atish Choudhury
18 papers · 1 as a fellow
WO
William Oh
16 papers
Sylvan Baca
15 papers · 10 as a fellow
CB
Connor Bell
13 papers · 6 as a resident
Jacob Berchuck
13 papers · 3 as a fellow
SA
Sarah Alaiwi
12 papers · 12 as a resident
SC
Stephen Chanock
12 papers
Adam Kibel
11 papers

Grants

Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making
National Cancer Institute · R01
PI · $1.2M · Dana-Farber Cancer Inst
2025–2030
DF/HCC Prostate SPORE
National Cancer Institute · P50
Project lead · $772.4K · Dana-Farber Cancer Inst
2023–2028
The Impact of DNA Damage Repair Abnormalities in Prostate Cancer
National Cancer Institute · P01
PI · $8.7M · Sloan-Kettering Inst Can Research
2019–2026
Defining the Epigenetic Landscape in Human Prostate Cancer
National Cancer Institute · R01
PI · $3.1M · Dana-Farber Cancer Inst
2015–2020

Clinical trials

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Principal investigator · Terminated · Phase 1
Mark Pomerantz, MD
2016–2017
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2015–2019
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2011–2017
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2003–2011